Analysts Anticipate Inspire Medical Systems (INSP) Will Announce Quarterly Sales of $14.00 Million

Equities research analysts predict that Inspire Medical Systems (NASDAQ:INSP) will report $14.00 million in sales for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Inspire Medical Systems’ earnings, with the highest sales estimate coming in at $14.10 million and the lowest estimate coming in at $13.90 million. The business is expected to issue its next earnings results on Tuesday, February 5th.

According to Zacks, analysts expect that Inspire Medical Systems will report full year sales of $48.00 million for the current year, with estimates ranging from $47.90 million to $48.10 million. For the next fiscal year, analysts forecast that the business will post sales of $63.33 million, with estimates ranging from $61.20 million to $64.50 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Inspire Medical Systems.

Inspire Medical Systems (NASDAQ:INSP) last posted its earnings results on Tuesday, November 6th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.13. The firm had revenue of $13.10 million during the quarter, compared to analyst estimates of $12.86 million. During the same period in the previous year, the company posted ($3.42) EPS. Inspire Medical Systems’s revenue for the quarter was up 79.9% compared to the same quarter last year.

Several equities analysts have recently commented on INSP shares. Zacks Investment Research downgraded Inspire Medical Systems from a “hold” rating to a “sell” rating in a research report on Wednesday, November 21st. Leerink Swann started coverage on Inspire Medical Systems in a research report on Monday, October 29th. They issued an “outperform” rating and a $57.00 target price on the stock. Finally, Berenberg Bank started coverage on Inspire Medical Systems in a research report on Wednesday, November 28th. They issued a “sell” rating and a $31.00 target price on the stock. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the stock. Inspire Medical Systems presently has a consensus rating of “Hold” and an average price target of $39.63.

In related news, Director Jerry C. Griffin sold 1,300 shares of the stock in a transaction that occurred on Tuesday, December 11th. The stock was sold at an average price of $37.60, for a total transaction of $48,880.00. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Timothy P. Herbert sold 15,000 shares of the stock in a transaction that occurred on Tuesday, December 18th. The stock was sold at an average price of $42.88, for a total value of $643,200.00. The disclosure for this sale can be found here. Insiders have sold 41,300 shares of company stock worth $1,694,130 in the last three months.

A number of large investors have recently modified their holdings of the stock. Orbimed Advisors LLC bought a new stake in Inspire Medical Systems during the second quarter worth $87,161,000. Millennium Management LLC bought a new stake in Inspire Medical Systems during the second quarter worth $26,752,000. BlackRock Inc. bought a new stake in Inspire Medical Systems during the second quarter worth $19,624,000. FMR LLC bought a new stake in Inspire Medical Systems during the second quarter worth $11,340,000. Finally, Federated Investors Inc. PA bought a new stake in Inspire Medical Systems during the second quarter worth $10,949,000.

Shares of Inspire Medical Systems stock traded down $0.08 on Thursday, hitting $41.95. The stock had a trading volume of 136,310 shares, compared to its average volume of 207,312. Inspire Medical Systems has a twelve month low of $22.50 and a twelve month high of $57.87.

About Inspire Medical Systems

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.

Recommended Story: Why is the Consumer Price Index (CPI) important?

Get a free copy of the Zacks research report on Inspire Medical Systems (INSP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Inspire Medical Systems (NASDAQ:INSP)

Receive News & Ratings for Inspire Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inspire Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply